Moreover, patients with the non-missense deleterious mutations had a higher susceptibility to cancer development (mainly due to lymphoma and carcinomas) in comparison to cases with missense TNFRSF13B mutations (27.2% vs. 7%, P = 0.001). This evidence concerns the gene TNFRSF13B and cancer.